How do you customize a personalized compound library?

Clients build libraries of suitable compounds for their research by selecting compounds from our inventory.

Are compounds for specific targets available?

Yes, we support customized development. If you have specific target needs, please contact the technical support team, and we will provide compound library screening or molecular design services.

Can I purchase individual compounds for in vivo research if I am only interested in specific molecules?

Certainly. At Protheragen, we offer the flexibility to purchase any compound from our libraries as a standalone product. If your research focuses on specific molecules, you can order them individually in the quantities required for intensive in vivo studies.

Inquiry

Products

Online Inquiry

Others

Inquiry

Other Bioactive Compounds Features Publication Applications Advantages FAQs

Overview

In the study of obesity and related metabolic diseases, the regulation of non-classical cellular signaling pathways has become a key area for breakthrough discoveries. In order to help researchers in the field of life sciences and medicine to deeply explore the complex regulatory mechanisms, Protheragen provides products covering a wide range of compounds, such as inhibitors, agonists, modulators, degraders, etc., focusing on targeting understudied signaling nodes and novel targets.

Non-classical Signaling Pathway Regulatory Compounds

Small Molecular Inhibitors

Our small molecule inhibitor products target novel receptors, enzymes, or ion channels to block non-traditional signaling cascades.

Agonists/ Antagonists

Our agonist/antagonist products mimic physiological signals by modulating specific receptors or signaling pathways to study their effects on obesity.

Modulators

Our modulator products are used to regulate metabolic processes or signaling to study their role in obesity.

Degraders

Our degradant products are used to degrade specific proteins or molecules, revealing their function in obesity.

Fig.1 Schematic overview of potential IL-4Rα contribution to HF+HC-driven obesity and obesity-associated metabolic derangements. (Damen, et al., 2021) Fig.1 Influence of potential factors on metabolic disorders in obesity. (Damen, et al., 2021)

Publication Data

Title: Non-hematopoietic IL-4Rα expression contributes to fructose-driven obesity and metabolic sequelae

Journal: International Journal of Obesity, 2021

DOI: https://doi.org/10.1038/s41366-021-00902-6

Summary: This paper focuses on the effects of interleukin-4Rα-deficient (IL-4Rα) in a high-fat, high-sugar diet-induced obesity model. IL-4Rα modulates high fat (HF) plus high carbohydrate (HC/fructose) diet (HF+HC) diet-induced weight gain, systemic adiposity, adipose tissue inflammatory gene expression, energy expenditure, exercise activity, glucose metabolism, hepatic steatosis, hepatic inflammatory gene expression, and hepatocyte injury. These effects were partially dependent on non-hematopoietic cell IL-4Rα expression but were not associated with direct signal transducer and activator of transcription 6 (STAT6) activation. Non-hematopoietic cell IL-4Rα was found to regulate the severity of high-fat, high-sugar diet-induced obesity and its associated sequelae through activation of nonclassical signaling pathways.

Fig.2 Non-hematopoietic IL-4Rα expression impacts HF+HC-induced weight gain and associated sequelae. (Damen, et al., 2021) Fig.2 Effect of IL-4Rα expression on body weight. (Damen, et al., 2021)

Applications

Drug Development: Our high-purity compounds accelerate drug candidate screening and efficacy validation. Beyond lead identification, our high-purity compounds ensure accurate PD/PK profiling and dose-response quantification, effectively bridging the gap between benchtop research and preclinical trials.
High-throughput Screening: Our libraries are meticulously formatted to ensure seamless integration into automated HTS platforms, significantly reducing assay variability and technical noise. By providing a chemically diverse and pre-validated collection of molecules, we empower researchers to rapidly identify high-affinity lead compounds, thereby drastically shortening the timeline of the initial hit-to-lead discovery phase.
Mechanism Exploration: Our products act as high-resolution chemical probes to dissect the intricate crosstalk within non-classical metabolic axes, such as the thermogenic activation of brown adipose tissue and the bidirectional communication of the gut-brain-liver axis. These tools enable scientists to resolve cryptic regulatory nodes in host-microbiome interactions, uncovering novel pathways for systemic metabolic homeostasis.

Advantages of Us

Multi-Dimensional Research Toolkit

From inhibitors to degraders, Protheragen provides a comprehensive tool chain spanning from classic small-molecule inhibitors to advanced degraders (e.g., PROTACs). This enables researchers to conduct multi-dimensional mechanistic studies, including signaling blockade, functional activation, and targeted protein clearance, offering unparalleled flexibility in dissecting complex biological pathways.

Stringent Validation for Peak Purity and Activity

To guarantee the highest standards of experimental integrity, all products undergo rigorous multi-stage testing, including high-performance liquid chromatography (HPLC), nuclear magnetic resonance (NMR), and liquid chromatography–mass spectrometry (LC-MS). These stringent quality control protocols ensure that every compound meets our exacting benchmarks for both chemical purity and biological activity, delivering consistent performance in every assay.

Superior Selectivity and Potency to Minimize False Positives

Protheragen's compounds are engineered for high potency and exquisite specificity. By ensuring robust interaction with intended targets while minimizing off-target effects, our products provide the potent selectivity required to generate clean, reliable data. This precision significantly reduces the risk of false-positive results, streamlining your path to validated discoveries.

Customer Review

Reliable Foundation for Preclinical Metabolic Profiling
"In our search for potent anti-obesity leads, Protheragen's compounds proved to be indispensable. Their exceptional purity allowed us to generate highly precise dose-response curves and robust PD/PK profiles without the interference of common synthesis artifacts." — Dr. Ke*** St**

Unlocking New Therapeutic Dimensions with Diverse Modulators
"The versatility of Protheragen's library—spanning from traditional signaling inhibitors to sophisticated protein degraders—has been a major asset to our mechanistic studies. Their ability to provide a complete tool chain allowed us to compare functional blockade with total protein clearance in a single study. The specificity of these probes is unmatched, consistently delivering clean data with minimal off-target noise." — Dr. So** Mo**, Senior Investigator

Frequently Asked Questions

How do you customize a personalized compound library?

Clients build libraries of suitable compounds for their research by selecting compounds from our inventory.
Are compounds for specific targets available?

Yes, we support customized development. If you have specific target needs, please contact the technical support team, and we will provide compound library screening or molecular design services.
Can I purchase individual compounds for in vivo research if I am only interested in specific molecules?

Certainly. At Protheragen, we offer the flexibility to purchase any compound from our libraries as a standalone product. If your research focuses on specific molecules, you can order them individually in the quantities required for intensive in vivo studies.

Protheragen provides high-purity and high-specificity compounds to support our clients' research in the field of obesity. If you don't find what you are looking for on our website, please feel free to contact us to solve your problem.

Reference

Damen, M.S.; et al. Non-hematopoietic IL-4Rα expression contributes to fructose-driven obesity and metabolic sequelae. International Journal of Obesity. 2021, 45(11): 2377-2387.